WAG Related Analyst Ratings
-
Barrington Research Downgrades Walgreen (WAG) to Market Perform
-
Walgreen (WAG) / Alliance Boots Synergies Tracking In-Line
-
AmerisourceBergen (ABC) Likely to Score Another Win Against McKesson (MCK)
-
AmerisourceBergen (ABC) Not Fully Reflecting Walgreens Deal - Goldman Sachs
-
Express Scripts (ESRX) Pricing Aggressively, Leerink Swann Maintains Buy
-
Macquarie Upgrades Walgreen (WAG) to Outperform
-
Cardinal Health (CAH) Needs CVS Renewal After Walgreen Loss - Analyst
-
Goldman Sachs Downgrades Walgreen (WAG) to Buy, Less Upside Potential
-
Citi Upgrades Walgreen (WAG) from Sell to Buy
-
JPMorgan Upgrades Walgreen (WAG) to Overweight
-
With Walgreen (WAG) Deal in Bag, AmerisourceBergen (ABC) Could Be Takeout Target
-
UPDATE: Walgreen (WAG) Ramps on UBS Upgrade; Invest for 'Big Picture'
-
Goldman Sachs Downgrades CVS Caremark (CVS) to Neutral, Few Catalysts
-
Mizuho Securities Upgrades Walgreen (WAG) to Buy
-
Goldman Lauds RadioShack's (RSH) New CEO Choice; Still Sees Challenges Ahead
-
Walgreen (WAG) Comps Make Strong Gains in January; May Signal Rebound
-
Standpoint Research Downgrades Walgreen (WAG) to Hold
-
Cantor Fitzgerald's Conviction Calls For 2013
-
Jefferies Upgrades Walgreen (WAG) to Buy
-
Raymond James Upgrades Walgreen (WAG) to Outperform
-
Goldman Sachs Lifts PT on Walgreen (WAG), Maintains Top Rating Post Q1 Noise
-
Christmas Comes Early For For Walgreen (WAG) Bulls
-
CVS (CVS) Taking Walgreen (WAG) Share - Analyst
-
Jefferies Cuts PT on Green Dot (GDOT), Sees Another Large Client May Move to AmEx (AXP)
-
Wal-Mart (WMT) Friendly Neighborhood Stores Have Sinister Plans for Competitor Walgreens (WAG)
-
Goldman Sachs Adds Walgreen (WAG) at Conviction Buy List, Earnings Growth to Reaccelerate
-
Leerink Swann on Pharmacy Benefit Managers: TRICARE Excludes Walgreen (WAG) from Network, Positive for Express Scripts (ESRX)
-
Jefferies Maintains a 'Hold' on Walgreen (WAG); Goodbye TRICARE
-
Jefferies Reiterates a 'Buy' on Express Scripts (ESRX); On Track With Narrow Network Strategy
-
Morgan Stanley Upgrades Walgreen (WAG) to Equalweight
-
Cantor Fitzgerald Starts CVS Caremark (CVS) at Buy; Riding the Generic Wave
-
Cantor Fitzgerald Starts Walgreen (WAG) at Buy; Damage Done, Look Past Transition Year
-
Jefferies Maintains a 'Hold' on Walgreen (WAG); Key Takeaways From NYC Meeting w/ Mgmt
-
UPDATE: UBS Downgrades Walgreen (WAG) to Neutral
-
ISI Group Starts Walgreen (WAG) at Underweight
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); OraQuick HIV-OTC Test in 30,000 Locations
-
Goldman Sachs Maintains a 'Neutral' on Rite-Aid (RAD); Same-Store Sales Reflect Impact of Generics
-
Morgan Stanley Says Express Scripts (ESRX) Customers Becoming Cozy with Rite Aid (RAD)
-
Argus Downgrades Walgreen (WAG) to Hold
-
Macquarie Downgrades Walgreen (WAG) to Neutral
-
UBS Reiterates a 'Neutral' on Rite-Aid (RAD); A Few Longer-Term Tailwinds, But Staying Sidelined For Now
-
Stifel Nicolaus Starts Walgreen (WAG) at Buy
-
UBS Maintains a 'Buy' on Cardinal Health (CAH); Color on Safeway Contract
-
UBS Raises Numbers on CVS Caremark (CVS); Comments From Conference Call
-
UBS Maintains a 'Buy' on Walgreen (WAG); Downside Risk Priced In, Creating Favorable Risk/Reward Balance
-
Analyst Calls Bid for Rite Aid (RAD) by Walgreen (WAG) 'Highly Unlikely'
-
Analyst Thinks Walgreen (WAG) Acquiring Rite Aid (RAD) 'Makes Sense'
-
BofA/Merrill Lynch Cuts Walgreen (WAG) to Underperform
-
Jefferies Maintains a 'Buy' on Express Scripts (ESRX); Incurs High Q4 Expenses As Its Preps For MHS Integration
-
Jefferies Maintains a 'Buy' on CVS Caremark (CVS); A Superior Model
Back to WAG Stock Lookup
